Exosome Diagnostics, CareFirst partner to speed up coverage for diagnostic tests

Ruhman joins NewcrestImage with more than 20 years of hospitality experience in senior management positions.
The partnership with Exosome Diagnostics is part of CareFirst's HealthWorx program, under which the insurance provider works with early-stage companies to accelerate health plan coverage of their products.

Liquid biopsy player Exosome Diagnostics is partnering with CareFirst BlueCross BlueShield to create evidence development studies for the evaluation of its EvoDx tests.

The agreement is part of CareFirst’s HealthWorx program, under which it works with early-stage companies to bring new technology to its members that could improve healthcare and reduce costs. They will assess new tests using clinical outcomes and cost analyses, with the goal of speeding up coverage for products that have “measurable benefits for patient care,” according to a statement.

Specifically, Exosome Diagnostics and CareFirst will work to demonstrate the clinical utility of the former’s tests, according to the statement. The pair will choose diagnostic tests for studies, the study endpoints and “the extent and qualifications of the providers participating in these studies.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The technology assessment and coverage determination process have been significant challenges for companies with innovative molecular diagnostic tests,” the companies said in the statement.

RELATED: Exosome Diagnostics teams with Amgen for liquid biopsy test development

First, the pair will focus on Exosome Diagnostics’ ExoDx Prostate Intelliscore (EPI) test, which is designed to rule out high-grade prostate cancer in patients, sparing them from an invasive biopsy. Prostate-specific antigen (PSA) screenings return a “relatively high number” of false positives, resulting in men with benign cases of low-grade cancers undergoing uncomfortable biopsies, said CareFirst Chief Medical Officer Rahul Rajkumar, M.D.

“The success of our companion diagnostics business and the launch of our point of care diagnostic system are important components of that strategy,” said Exosome Diagnostics CEO John Boyce in the statement. “Now our diagnostics business will benefit from CareFirst’s commitment to creating a better way to develop timely and informed decisions about which molecular diagnostic tests bring value for their members and providers. We look forward to working with CareFirst on the launch of future diagnostic and companion diagnostic tests in our pipeline.”

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.